Investors



Investor FAQ

Show all

Strongbridge Biopharma is an Irish public limited company.
The U.S. operations are based in Trevose, Pennsylvania, USA.
Strongbridge Biopharma was established in 1996.
Strongbridge Biopharma priced its initial public offering on NASDAQ Global Market on October 16, 2015 and trades under the ticker symbol SBBP.
Strongbridge Biopharma’s CUSIP number is G85347 105.
Communication regarding transfer requirements, lost certificates, changes of address, etc., should be directed to: Computershare

Written Inquiries:

Computershare
PO Box 43001
Providence RI 02940-30001

Or by overnight delivery:
Computershare
250 Royall St.
Canton, MA 02021

Email Inquiries:
web.queries@computershare.com

Telephone Inquiries:
Toll-Free: 866-490-6058 (US, Canada, Puerto Rico)
781-575-2784 (non-US)

Online Inquiries:
https://www-us.computershare.com/investor/Contact
Strongbridge Biopharma’s fiscal year end is December 31.
You may sign up to receive Strongbridge Biopharma’s press releases and SEC filings at the following link: Email Alerts.
Strongbridge Biopharma’s U.S. Securities and Exchange Commission filings can be viewed on the SEC page.
For investor relations inquiries, you may submit inquiries via investors@strongbridgebio.com, or by contacting Marcy Nanus at The Trout Group, LLC. at +1-646-378-2927 or mnanus@troutgroup.com.

For corporate or media relations inquiries, you may submit inquiries via media@strongbridgebio.com, or by contacting Lindsay Rocco at Elixir Health Public Relations at +1-862-596-1304 or lrocco@elixirhealthpr.com.






© 2017 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA is a trademark of Strongbridge Biopharma plc.
KEVEYIS ® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V11 10/2017

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
info@strongbridgebio.com

Privacy Statement
Comprehensive Compliance Program
California Statement of Compliance